Funder
Pfizer, Inc.
Ministry of Science and Technology, Taiwan
Publisher
Springer Science and Business Media LLC
Subject
Health Policy,Economics, Econometrics and Finance (miscellaneous)
Reference29 articles.
1. Terwilliger, T., Abdul-Hay, M.: Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J. 7(6), e577 (2017). https://doi.org/10.1038/bcj.2017.53
2. Uy, N., Nadeau, M., Stahl, M., Zeidan, A.M.: Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia. J. Blood Med. 9, 67–74 (2018). https://doi.org/10.2147/jbm.S136575
3. Health Promotion Administration Taiwan (2015) Taiwan Cancer Registry Annual Report. https://www.hpa.gov.tw/Pages/Detail.aspx?nodeid=269&pid=8084. Accessed 14 Aug 2018
4. Kantarjian, H.M., DeAngelo, D.J., Stelljes, M., Martinelli, G., Liedtke, M., Stock, W., Gokbuget, N., O'Brien, S., Wang, K., Wang, T., Paccagnella, M.L., Sleight, B., Vandendries, E., Advani, A.S.: Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N. Engl. J. Med. 375(8), 740–753 (2016). https://doi.org/10.1056/NEJMoa1509277
5. Hung, M.C., Lai, W.W., Chen, H.H., Lee, J.C., Lin, Y.J., Hsiao, J.R., Cheng, Y.M., Shan, Y.S., Su, W.C., Wang, J.D.: Cost effectiveness of cancer treatment in Taiwan. J. Formos. Med. Assoc. 115(8), 609–618 (2016). https://doi.org/10.1016/j.jfma.2016.04.002
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献